Need a specific person's email?
Browse LeonaBio's employee directory (about 56 employees) and reveal verified emails free.
LeonaBio's most common email format is First.Last@athira.com (ex. John.Doe@athira.com), used for 96% of athira.com addresses. LeonaBio uses 6 email patterns across 2 domains: athira.com and leonabio.com. Percentages are the share of addresses within each domain.
| Format | Example | Share of athira.com |
|---|---|---|
| First.Last@athira.comMost common | John.Doe@athira.com | |
| F-Last@athira.com | J-Doe@athira.com | |
| First.Middle@athira.com | John.Michael@athira.com | |
| FirstMLast@athira.com | JohnMDoe@athira.com |
| Format | Example | Share of leonabio.com |
|---|---|---|
| First.Last@leonabio.comMost common | John.Doe@leonabio.com | |
| First.MiddleLast@leonabio.com | John.MichaelDoe@leonabio.com |
Browse LeonaBio's employee directory (about 56 employees) and reveal verified emails free.
Biotechnology ResearchWashington, United States51-200 Employees
LeonaBio is a clinical-stage biotechnology company focused on developing novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and ALS. It is headquartered in Bothell, Washington, and employs 51 to 200 people. The company holds a license to a Phase 3 Lasofoxifene program, a selective estrogen receptor modulator, pursuing a registrational study in ESR1-mutated metastatic ER-positive, HER2-negative breast cancer, with enrollment expected to complete in 4Q26 and topline data anticipated in 2H27. It also plans a Phase 2 proof-of-concept study of ATH-1105 in ALS in the second half of 2026. LeonaBio has expanded its governance through new board appointments and engages with the scientific community through presentations and industry conferences in 2026.
Most common format
First.Last@athira.com
Example: John.Doe@athira.com
Free with a LeadIQ account. No credit card.
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.